iSpecimen

iSpecimen

ISPC
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

ISPC · Stock Price

USD 5.29+4.15 (+364.85%)
Market Cap: $6.6M

Historical price data

Overview

iSpecimen's mission is to accelerate medical discovery by creating an efficient, digital marketplace for human biospecimens, connecting researchers with providers globally. Its core achievement is the development of the iSpecimen Marketplace®, a platform that aggregates millions of samples, standardizes data, and manages the complex logistics and compliance of specimen procurement. The company's strategy focuses on scaling its global provider network, enhancing its platform's data capabilities, and capturing a larger share of the multi-billion-dollar biospecimen market to drive sustainable revenue growth.

OncologyNeurologyAutoimmuneInfectious DiseaseCardiovascularGastrointestinalWomen's Health

Technology Platform

The iSpecimen Marketplace® is a global digital B2B platform that connects researchers with healthcare providers to streamline the search, procurement, and logistics of human biospecimens with associated clinical data.

Opportunities

The multi-billion dollar biospecimen market is highly fragmented and inefficient, driven by growing precision medicine R&D.
iSpecimen's digital marketplace model is poised to capture share by providing unmatched access, data richness, and procurement efficiency for researchers globally.

Risk Factors

Key risks include failure to achieve network liquidity and scale, regulatory compliance breaches in handling sensitive human data and materials, ongoing financial losses and cash burn, and intense competition from established biobanks and new digital entrants.

Competitive Landscape

iSpecimen competes with large traditional biobanks/CROs (e.g., BioIVT, Charles River) and emerging digital platforms. Its differentiation lies in its dedicated B2B marketplace model, integrated compliance/logistics, and focus on creating a network effect between global providers and researchers.